TODDLERS should be tested for high levels of cholesterol to identify whether they are at risk of premature heart disease, researchers say.
An interesting article regarding a possible screening program to identify high cholesterol in children - would be great to be able to know, so as to be able to manage food, stress levels etc early on, and reduce the effects of this problem. Hopefully the research into this screening continues.
Source: http://www.news.com.au/dailytelegraph/story/0,22049,22775764-5006007,00.html?from=public_rss
"A national screening program, which would involve a prick of the child's finger, could help to cut the increasing number of people with hereditary high cholesterol.
About one in 500 people are affected by familial hypercholesterolaemia, which is passed on in the genes and carries a much greater risk of premature death in young adults.
The study found that screening would have a double benefit because it would identify that at least one of the baby's parents was also at risk.
Dr Edwin Kirk, of the Sydney Children's Hospital at Randwick, said theoretically the strategy made sense, but a pilot study would establish its likely success."
Tuesday, November 20, 2007
Friday, November 16, 2007
Preclinical Studies of the Mechanism for defective cholesterol transport in Diabetes patients
Great news here re: cholesterol control for patients with diabetes. Good on you guys at Synvista Therapeutics Inc. for some great research.
Article source: http://www.medicalnewstoday.com/articles/87758.php
"Synvista Collaboration Demonstrates In Preclinical Studies The Mechanism For Defective Cholesterol Transport In ...
Synvista Therapeutics, Inc. (Amex: SYI) announced results of a series of preclinical studies designed to explain the mechanism underlying dysfunctional high density lipoprotein (HDL), that creates a defect in reverse cholesterol transport in patients with Diabetes Mellitus (DM). The studies reveal that a common blood protein, Haptoglobin, binds to the core of HDL and that a defective Haptoglobin variant (Hp2-2), found in 40% of the population, may induce dysfunctionality in HDL. Further, the studies report that exposure to Vitamin E can restore HDL functionality and the process of reverse cholesterol transport. The study is being presented today at the American Heart Association's (AHA) Scientific Sessions 2007 in Orlando, Florida.
"We are very pleased with the outcome of these studies, as we believe they provide scientific rationale for our current development platform, including our work developing a diagnostic test for Haptoglobin type, to determine cardiovascular risk and a therapeutic product to decrease HDL oxidation and restore reverse cholesterol transport function," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista."
Article source: http://www.medicalnewstoday.com/articles/87758.php
"Synvista Collaboration Demonstrates In Preclinical Studies The Mechanism For Defective Cholesterol Transport In ...
Synvista Therapeutics, Inc. (Amex: SYI) announced results of a series of preclinical studies designed to explain the mechanism underlying dysfunctional high density lipoprotein (HDL), that creates a defect in reverse cholesterol transport in patients with Diabetes Mellitus (DM). The studies reveal that a common blood protein, Haptoglobin, binds to the core of HDL and that a defective Haptoglobin variant (Hp2-2), found in 40% of the population, may induce dysfunctionality in HDL. Further, the studies report that exposure to Vitamin E can restore HDL functionality and the process of reverse cholesterol transport. The study is being presented today at the American Heart Association's (AHA) Scientific Sessions 2007 in Orlando, Florida.
"We are very pleased with the outcome of these studies, as we believe they provide scientific rationale for our current development platform, including our work developing a diagnostic test for Haptoglobin type, to determine cardiovascular risk and a therapeutic product to decrease HDL oxidation and restore reverse cholesterol transport function," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista."
Monday, November 12, 2007
Charity warns of cholesterol 'time bomb'
URGENT action is needed to tackle high cholesterol levels in Scotland, a report warns.
The charity Heart UK said that high cholesterol was a major risk-factor for stroke and heart disease, which cost the Scottish economy more than £1.8 billion a year - a burden that is set to worsen as the population ages.
The charity's report calls for a review of NHS cholesterol-lowering targets, which it said only drove the NHS to achieve a minimum standard of care.
Michael Livingston, the Heart UK director, said: "If Scotland and the rest of the UK are to avoid a demographic time bomb and maintain the welfare state, we need to tackle the issue of high cholesterol levels."
Shona Robison, the public health minister, is speaking at the launch of the report in the Scottish Parliament today.
Source: http://news.scotsman.com/scotland.cfm?id=1767322007
The charity Heart UK said that high cholesterol was a major risk-factor for stroke and heart disease, which cost the Scottish economy more than £1.8 billion a year - a burden that is set to worsen as the population ages.
The charity's report calls for a review of NHS cholesterol-lowering targets, which it said only drove the NHS to achieve a minimum standard of care.
Michael Livingston, the Heart UK director, said: "If Scotland and the rest of the UK are to avoid a demographic time bomb and maintain the welfare state, we need to tackle the issue of high cholesterol levels."
Shona Robison, the public health minister, is speaking at the launch of the report in the Scottish Parliament today.
Source: http://news.scotsman.com/scotland.cfm?id=1767322007
Subscribe to:
Posts (Atom)